« From The WorldNetDaily: The Death of Palestinianism | Main | Hyscience Fees and Services »

November 11, 2004

A Case of Rofecoxib-Associated Stevens-Johnson Syndrome with corneal And Conjunctival Changes

Topics:

Vioxx Case Report
Cornea. 2004 Oct;23(7):736-7.
Goldberg D, Panigrahi D, Barazi M, Abelson M, Butrus S.
Department of Ophthalmology, The Georgetown University-Washington Hospital Center, Washington, DC, USA.

Reporting a case of rofecoxib (Vioxx)-associated Stevens-Johnson syndrome with corneal and conjunctival changes. Experimental Design: Interventional case report. Methods: Case report of a 62-year-old woman with systemic lupus erythematosus (SLE) taking rofecoxib for arthritis for 3 weeks. Results: Stevens-Johnson syndrome after 3 weeks of rofecoxib therapy. CONCLUSION: This case report suggests that oral rofecoxib may trigger Stevens-Johnson syndrome, potentially causing symblepharons, corneal neovascularization and cicatricial ectropions.

Vioxx continues to make the news in medical-jurisprudence circles. LegalUnderground reports today on the conference in Pasadena, California. Hyscience has previously reported on the arthritis medication Vioxx, which maker Merck voluntarily withdrew from the market in September, and how it might have contributed to an estimated 27,785 heart attacks and sudden cardiac deaths between 1999 and 2003, according to an FDA memo published online.

Posted by Hyscience at November 11, 2004 3:48 PM

Articles Related to :